Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Rapid Antidepressant Effects in MDD
NCT00088699Phase 2Completed
- Sponsor
- National Institute of Mental Health
- Start
- Jul 2004
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by National Institute of Mental Health. Primary endpoint: Montgomery-Asberg Depression Rating Scale at Day 1. Started Jul 2004; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00088699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088699.